CY1117855T1 - Διαδικασια για τη συνθεση των παραγωγων 3,6-διυδρο-1,3,5-τριαζινης - Google Patents

Διαδικασια για τη συνθεση των παραγωγων 3,6-διυδρο-1,3,5-τριαζινης

Info

Publication number
CY1117855T1
CY1117855T1 CY20161100394T CY161100394T CY1117855T1 CY 1117855 T1 CY1117855 T1 CY 1117855T1 CY 20161100394 T CY20161100394 T CY 20161100394T CY 161100394 T CY161100394 T CY 161100394T CY 1117855 T1 CY1117855 T1 CY 1117855T1
Authority
CY
Cyprus
Prior art keywords
procedure
triazine
dyhydro
producers
composition
Prior art date
Application number
CY20161100394T
Other languages
Greek (el)
English (en)
Inventor
Stéphanie AUBOURG
Bernard Boudet
Daniel Cravo
Matthias Helmreich
Original Assignee
Poxel S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel S.A.S. filed Critical Poxel S.A.S.
Publication of CY1117855T1 publication Critical patent/CY1117855T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20161100394T 2008-05-23 2016-05-11 Διαδικασια για τη συνθεση των παραγωγων 3,6-διυδρο-1,3,5-τριαζινης CY1117855T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08009483 2008-05-23
PCT/EP2009/002997 WO2009141040A2 (en) 2008-05-23 2009-04-24 Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
EP09749530.3A EP2300444B1 (en) 2008-05-23 2009-04-24 Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives

Publications (1)

Publication Number Publication Date
CY1117855T1 true CY1117855T1 (el) 2017-05-17

Family

ID=40791625

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100394T CY1117855T1 (el) 2008-05-23 2016-05-11 Διαδικασια για τη συνθεση των παραγωγων 3,6-διυδρο-1,3,5-τριαζινης

Country Status (21)

Country Link
US (1) US20110124860A1 (enExample)
EP (1) EP2300444B1 (enExample)
JP (1) JP5458093B2 (enExample)
KR (1) KR101618198B1 (enExample)
CN (1) CN102036970A (enExample)
AU (1) AU2009250149B2 (enExample)
BR (1) BRPI0912512B1 (enExample)
CA (1) CA2725011A1 (enExample)
CY (1) CY1117855T1 (enExample)
DK (1) DK2300444T3 (enExample)
EA (1) EA018921B1 (enExample)
ES (1) ES2571793T3 (enExample)
HR (1) HRP20160414T1 (enExample)
HU (1) HUE027532T2 (enExample)
IL (1) IL209198A (enExample)
MX (1) MX2010012741A (enExample)
PL (1) PL2300444T3 (enExample)
RS (1) RS54736B1 (enExample)
SI (1) SI2300444T1 (enExample)
WO (1) WO2009141040A2 (enExample)
ZA (1) ZA201009160B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2646422T3 (pl) 2010-12-01 2015-12-31 Poxel Rozdział enancjomerów pochodnych triazyny z zastosowaniem kwasu winowego
CN105753801B (zh) * 2016-03-25 2018-06-01 浙江工业大学 一种均三嗪类化合物的制备方法
JP2020536121A (ja) 2017-10-02 2020-12-10 ポクセルＰｏｘｅｌ 駆出率が保持された心不全を治療する方法
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
WO2019238647A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
CN114681464B (zh) * 2020-12-28 2024-07-09 南京理工大学 二甲双胍类似物在制备脑缺血再灌注损伤预防和治疗药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2003289375A1 (en) * 2002-12-17 2004-07-09 Hamari Chemicals, Ltd Novel 2,4-diamino-1,3,5-triazine derivative
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
DE102007054416A1 (de) * 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind

Also Published As

Publication number Publication date
WO2009141040A2 (en) 2009-11-26
PL2300444T3 (pl) 2016-08-31
JP2011520930A (ja) 2011-07-21
SI2300444T1 (sl) 2016-10-28
WO2009141040A3 (en) 2010-01-21
MX2010012741A (es) 2010-12-21
KR101618198B1 (ko) 2016-05-04
AU2009250149A1 (en) 2009-11-26
EA201001828A1 (ru) 2011-04-29
JP5458093B2 (ja) 2014-04-02
BRPI0912512B1 (pt) 2018-09-11
EP2300444A2 (en) 2011-03-30
DK2300444T3 (en) 2016-05-23
IL209198A0 (en) 2011-01-31
CN102036970A (zh) 2011-04-27
CA2725011A1 (en) 2009-11-26
KR20110013498A (ko) 2011-02-09
EA018921B1 (ru) 2013-11-29
US20110124860A1 (en) 2011-05-26
HUE027532T2 (en) 2016-10-28
EP2300444B1 (en) 2016-04-13
HRP20160414T1 (hr) 2016-05-20
BRPI0912512A2 (pt) 2015-07-28
RS54736B1 (sr) 2016-10-31
ES2571793T3 (es) 2016-05-26
AU2009250149B2 (en) 2013-05-23
IL209198A (en) 2013-11-28
ZA201009160B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
CY1117855T1 (el) Διαδικασια για τη συνθεση των παραγωγων 3,6-διυδρο-1,3,5-τριαζινης
CY1125421T1 (el) Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
CY1120389T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη
CY1118231T1 (el) Συνθεση λιποσωματος
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
CY1118157T1 (el) Εκλεκτικοι αναστολεις γλυκοσιδασης και χρησεις αυτων
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
CY1112724T1 (el) Παραγωγα ανθρακικης κουινουκλιδινης και ιατρικη συνθεση αυτων
CY1123919T1 (el) 1η-βενζιμιδαζολο-4-καρβοξαμιδια υποκατεστημενα με τεταρτοταγη ανθρακα στην 2-θεση ειναι ισχυροι αναστολεις parp
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
EA201170227A1 (ru) Имидазолкарбоксамиды
CY1113757T1 (el) Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων
CY1119826T1 (el) Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
CL2010001496A1 (es) Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina.
DOP2010000062A (es) Derivados de ciclopropilamida
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
CL2012000937A1 (es) Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad.
CY1113435T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
EA201100612A1 (ru) Новые производные 2-амидотиадиазола